Assembly Biosciences, Inc. (ASMB)

Market Cap	48.41M
Revenue (ttm)	n/a
Net Income (ttm)	-81.39M
Shares Out	52.61M
EPS (ttm)	-1.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,008
Open	0.910
Previous Close	0.924
Day's Range	0.900 - 0.910
52-Week Range	0.770 - 1.790
Beta	0.74
Analysts	Buy
Price Target	2.17 (+141.11%)
Earnings Date	Nov 7, 2023

About ASMB

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor ag...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 17, 2010
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: ASMB

Analyst Forecast

According to 3 analysts, the average rating for ASMB stock is "Buy." The 12-month stock price forecast is $2.17, which is an increase of 141.11% from the latest price.

Price Target

$2.17

(141.11% upside)

Analyst Consensus: Buy